Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY) concerning possible violations of federal securities laws between June 17, 2015 and August 10, 2017, inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the October 24, 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or you can e-mail him at firstname.lastname@example.org. No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. According to the Complaint, throughout the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. Upon release of this information, shares of Dr. Reddy's fell in value materially, which caused investors harm according to the Complaint. Lundin Law PC was founded by Brian Lundin, Esquire, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.